Navigation Links
Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
Date:5/30/2008

alth Sciences Center, and a principal study investigator. "A patient's A1C level is one of our primary markers in determining their risk of developing cardiovascular disease. These analyses show that adding Welchol to the most common type 2 diabetes regimens can help achieve additional A1C lowering across many different patient types."

Several mechanisms have been proposed for the glucose-lowering effect of Welchol, including reductions in glucose absorption and effects on glucose metabolism via nuclear receptors in the intestine and/or the liver. The exact mechanism(s) is under investigation.

About the Analyses

For both analyses, data was extracted from three double-blind, placebo-controlled, pivotal Welchol trials involving 1,018 patients. Welchol was added to either metformin-, insulin- or sulfonylurea-based therapy in patients with inadequately controlled type 2 diabetes (A1C 7.5% to 9.5%). The mean baseline A1C of patients in these studies was 8.1% to 8.3%. The primary endpoint in the pivotal Welchol trials was mean change from baseline in A1C. Mean change in LDL-cholesterol was a secondary endpoint.

In the first post-hoc analysis, efficacy parameters included change from baseline in A1C. All patients receiving Welchol were pooled (N=512) and stratified based on individual A1C reductions (greater than or equal to 0.5%, greater than or equal to 0.7%, and greater than or equal to 1.0%) from baseline to study end. The results from the post-hoc analyses found that almost half (47%) of the patients achieving a reduction of greater than or equal to 0.5% had a mean A1C reduction of 1.04% (P<0.001); 36% of patients achieving a reduction of greater than or equal to 0.7% had a mean A1C reduction of 1.20% (P<0.001); and 24.1% achieving a reduction of greater than or equal to 1.0% had a mean A1C reduction of 1.40% (P<0.001).

In the second post-hoc analysis, data from the pivotal studies were pooled and patients were stratified by age (gre
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
2. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
3. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
4. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
5. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
6. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
7. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
8. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
9. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
10. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
11. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vzhr6h/video ) has ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - ... has been the topic of fascination since the era of ... and the Soviet Russia. Earlier even a small glimpse ...
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for operable and inoperable solid tumor cancers, ... at the 7 th Annual Phacilitate Immunotherapy Forum in ... presentation at Phacilitate will take place on January 26 at ...
(Date:1/23/2015)... 2015  Pete Rose, baseball,s all-time hits leader, is the new ... Myoflex, Ducere Pharma has announced. "Pete,s a Hall ... have him on board with Myoflex," said Ducere Pharma Chief ... player who is known across all generations. The passion and ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2
... VION PHARMACEUTICALS,INC. (Nasdaq: VION ) today ... trial of its lead anticancer agent Cloretazine(R),(VNP40101M) in ... acute myelogenous leukemia (AML) and high-risk,myelodysplastic syndromes (MDS). ... Ellen K. Ritchie, M.D. at The Weill-Cornell Medical ...
... May Provide New Option for Clinicians Concerned About ... Systemic Exposure When Using an ... Inc. (NYSE: ALO ),a leading global specialty pharmaceutical ... week at the American Pain Society annual,meeting demonstrate the ...
Cached Medicine Technology:Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7
(Date:1/22/2015)... 2015 The City of West Hollywood hosted a ... commemorate the 42nd anniversary of the Supreme Court decision Roe v. ... 42 years since the Roe vs. Wade decision and the fight ... as ever,” said City of West Hollywood Councilmember Abbe Land. “We ...
(Date:1/22/2015)... 22, 2015 Gabe’s Chemo Duck Program is pleased ... first app ever created for kids with cancer. The Chemo Duck ... devices, is filled with enjoyable games to help children of all ... free app helps to keep kids entertained, educated and at ease ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently ... thrilled to have it lead the wedding dress industry into ... prom dresses for the global market. , “The CEO of ... he focuses on continuing the goal of operational excellence and ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering ... follow it on Facebook, Twitter, and Pinterest. The fans will ... draws a lottery every week. , Moreover, the company has ... Click Angelweddingdress homepage for more information. , ...
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... Asch, MD, MBA, the Robert D. Eilers Professor of Medicine ... Pennsylvania School of Medicine and the Wharton School, was presented ... Award by the Association American of Medical Colleges (AAMC). ... association,s annual meeting in Boston. Recognizing Dr. ...
... recovery may actually prevent happiness, researchers say , TUESDAY, Nov. ... the hope that they will get better may actually lead ... important part of happiness, but there,s a dark side of ... with their life, it can get in the way of ...
... ... ... 2009 -- Entest BioMedical, Inc. (OTCBB: ENTB) discussed its current therapies in development ... and their potential to generate significant revenue for the Company., , ,1.   Immuno-therapeutic treatment of ...
... LOS ANGELES, Nov. 10 Research conducted by the Center ... on the effects of a popular form of hyperbaric oxygen ... The "Randomized Trial of Hyperbaric Oxygen Therapy for Children with ... at 1.3 atmospheres of pressure, does not have a significant ...
... ... concern for many Americans and when the future of health is very ... the United States. Consumers now have more options to consider when making ... than now. Easy Pha-max provides superior quality plant-based nutritional products that can ...
... ... expanding its cutting edge vibration exercise technology into South America, beginning in Argentina, Chile ... and Contour Plus, are now available in South America. , ... (Vocus) November 10, 2009 -- WAVE (Whole-Body ...
Cached Medicine News:Health News:David A. Asch, M.D., M.B.A., receives AAMC Distinguished Teacher Award 2Health News:Acceptance of Chronic Illness Helps People Move On 2Health News:Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company 2Health News:Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company 3Health News:Center for Autism and Related Disorders Study Finds Hyperbaric Oxygen Therapy Ineffective Treatment for Children with Autism 2Health News:Major Biotechnology Franchise Company Expands Rapidly Throughout the USA Amidst Mounting Health Concerns 2Health News:WAVE's Revolutionary Whole-Body Advanced Vibration Exercise Is Now Available in South America 2
McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....
West lacrimal cannula, blunt tip, 0.3 mm side opening....
Lacrimal cannula, malleable tip, straight....
The first easy-to use peroxide system offers proven efficacy that's pure and simple. The convenience of a multi-purpose cleaner/rinse in one bottle. Added power of peroxide in the other bottle....
Medicine Products: